15.90
전일 마감가:
$16.03
열려 있는:
$16.19
하루 거래량:
69,053
Relative Volume:
0.72
시가총액:
$211.16M
수익:
$116.26M
순이익/손실:
$-11.08M
주가수익비율:
-20.08
EPS:
-0.7917
순현금흐름:
$1.04M
1주 성능:
+8.82%
1개월 성능:
+9.94%
6개월 성능:
+61.79%
1년 성능:
+47.27%
Anika Therapeutics Inc Stock (ANIK) Company Profile
명칭
Anika Therapeutics Inc
전화
(781) 457-9000
주소
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ANIK
Anika Therapeutics Inc
|
15.87 | 213.29M | 116.26M | -11.08M | 1.04M | -0.7917 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.96 | 53.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.84 | 42.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.65 | 41.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
76.29 | 31.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
563.70 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | B. Riley Securities | Buy |
| 2024-11-01 | 재확인 | Barrington Research | Outperform |
| 2023-08-14 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 재개 | Stephens | Equal-Weight |
| 2022-03-09 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 개시 | Stephens | Overweight |
| 2021-07-16 | 개시 | UBS | Neutral |
| 2020-12-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | 업그레이드 | Sidoti | Neutral → Buy |
| 2020-01-10 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 개시 | BWS Financial | Sell |
| 2019-09-24 | 재확인 | Barrington Research | Outperform |
| 2019-09-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | 업그레이드 | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2018-07-27 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 재확인 | Barrington Research | Outperform |
| 2016-05-09 | 업그레이드 | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 재확인 | Barrington Research | Outperform |
모두보기
Anika Therapeutics Inc 주식(ANIK)의 최신 뉴스
Price to book forward of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView
Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine - Traders Union
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell 2000 Defensive Index - marketscreener.com
Early MRI scans uncover hidden risks in rotator cuff repair, Integrity Implant System data show - Traders Union
Anika Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANIK) - TradingView
ANIK Forecast — Price Target — Prediction for 2027 - TradingView
Anika Therapeutics unveils Hyalofast cartilage repair scaffold using Hyaff hyaluronic acid technology - Traders Union
Behavioral Patterns of ANIK and Institutional Flows - Stock Traders Daily
Anika Shareholders Approve Directors and Expanded Incentive Plans - TipRanks
Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant - Stock Titan
Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares - Stock Titan
Anika Therapeutics (ANIK) director awarded 10,402 RSUs in stock grant - Stock Titan
[Form 4] Anika Therapeutics, Inc. Insider Trading Activity - Stock Titan
Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant - Stock Titan
Anika Therapeutics increases equity plan shares under amended omnibus and ESPP - TradingView
Anika Therapeutics (NASDAQ: ANIK) shareholders back equity plans and director slate - Stock Titan
Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biologics may shift outcomes in tendon injuries, Anika Therapeutics explores - Traders Union
Anika Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Anika Therapeutics Inc (ANIK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anika Therapeutics Inc (ANIK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Anika Therapeutics Inc (ANIK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Anika Therapeutics Inc (ANIK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Anika Therapeutics Inc (ANIK) Institutional Confidence - TradingKey
Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Anika Therapeutics introduces Cingal as only approved HA and corticosteroid combination for OA pain - Traders Union
(ANIK) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Anika Therapeutics (ANIK) Holds Steady Near Support Amid Low VolumeMonthly Profile - newsline.com
Anika Therapeutics Q1 2026 Earnings: Massive EPS Beat Fuels OptimismConsensus Forecast Report - newsline.com
Anika Therapeutics (ANIK) Edges Higher as Shares Test Key Resistance LevelsInside Day Breakout - newsline.com
Anika reports inducement grants - Medical Buyer
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Anika Therapeutics grants 3,360 RSUs to new employee as inducement under Nasdaq rules. - Pluang
New Anika hire receives 3,360 stock units as job inducement - Stock Titan
Anika (NASDAQ: ANIK) CEO exercises RSUs, withholds shares to cover tax - Stock Titan
Anika Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Griffin Stephen D. - Moomoo
Anika Therapeutics introduces proprietary Hyaff material for next generation regenerative applications - Traders Union
How (ANIK) Movements Inform Risk Allocation Models - Stock Traders Daily
Anika Therapeutics (ANIK) Holds Steady Near Support as Slight Decline PersistsIV Contraction - thelegaladvocate.com
Anika Therapeutics (ANIK) Hovers Near Support With Minimal Price MovementAndrews Pitchfork - dars.gov.et
ANIKAnika Therapeutics Inc Stock Price and Quote - Finviz
Anika Therapeutics (ANIK) Slides 1.6% Amidst Market Pressure – Key Levels to WatchOrder Block - The Legal Advocate
ANIK Stock Analysis: Anika Therapeutics Inc. gains 3.31 percent daily, trades at 14.98 dollar - Newser
Anika Therapeutics (ANIK) Holds Near Support After Slight DeclineIntraday Profile - newsline.com
ORIC Stock Heads Into Weekend as Cancer-Trial Deadline Approaches - Bez Kabli
Trading Systems Reacting to (ANIK) Volatility - Stock Traders Daily
Anika Therapeutics (ANIK) Q1 2026 Earnings: Surprise EPS Beat Amid Revenue UncertaintyAnnual Financial Report - newsline.com
ANIK Q1 2026 Earnings: Surprise Profit Swing as Anika Therapeutics Beats ExpectationsAnnual Earnings Summary - Newser
Anika Therapeutics Inc (ANIK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anika Therapeutics Inc 주식 (ANIK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Griffin Stephen D. | President and CEO |
Apr 30 '26 |
Buy |
12.29 |
12,200 |
149,881 |
36,163 |
자본화:
|
볼륨(24시간):